Published peptide research references

LL-37

Governed registry record

25 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.

Open the peptide evidence profile →

Approved source records

Cathelicidin LL-37-Induced Transcriptome of Human Keratinocyte Identifies Chemokine CXCL10 Link to T-Cell-Mediated Rosacea Pathogenesis through Jak1/STAT1 Pathway.
Abdul W Ansari; Tanwir Habib; Fareed Ahmad; Thesni Raheed; Cynthia S Elizabeth; Sara Al-Harami; Anh Jochebeth; Martin Steinhoff · The Journal of investigative dermatology · 2026
DOI: 10.1016/j.jid.2025.08.003 PMID: 40835085
Study of cathelicidin (LL-37) immunoexpression in the skin of vitiligo patients.
Lamia Hamouda Elgarhy; Basma Ramadan Refaey Ramadan; Fersan Abd Allah Sallam; Dalya Ayman Iskandarani; El-Sayed Shaaban Hewedy · Archives of dermatological research · 2025
DOI: 10.1080/09546634.2020.1757018 PMID: 39873762
Cathelicidin LL-37 promotes wound healing in diabetic mice by regulating TFEB-dependent autophagy.
Liuqing Xi; Juan Du; Wen Xue; Kan Shao; Xiaohong Jiang; Wenfang Peng; Wenyi Li; Shan Huang · Peptides · 2024
DOI: 10.1016/j.peptides.2024.171183 PMID: 38423213
Human Cathelicidin, LL-37 a potential antiviral therapeutic for Rift Valley Fever Virus in Egypt.
Engy M Ahmed; Abeer A Boseila; Amro S Hanora; Samar M Solyman · Cellular and molecular biology (Noisy-le-Grand, France) · 2024
DOI: 10.14715/cmb/2024.70.8.1 PMID: 39262269
Salivary Cathelicidin (LL-37) in Children and Adolescents Living with HIV.
Ana Lucia Seminario; Ashley E Karczewski; Whasun Chung; Yan Wang; Dalton Wamalwa; Sarah Benki-Nugent; Grace John-Stewart; Jennifer A Slyker; Arthur Kemoli · Biomedicine hub · 2024
DOI: 10.1159/000535596 PMID: 38287973
Vitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity.
Alexandra Aidoukovitch; Elisabeth Bankell; Daniel Svensson; Bengt-Olof Nilsson · Biochemical and biophysical research communications · 2024
DOI: 10.1016/j.bbrc.2024.149962 PMID: 38642493
Cathelicidin (LL-37) causes expression of inflammatory factors in coronary artery endothelial cells of Kawasaki disease by activating TLR4-NF-κB-NLRP3 signaling.
Feifei Si; Yaheng Lu; Yizhou Wen; Tingting Chen; Yingzi Zhang; Yanfeng Yang · Immunity, inflammation and disease · 2023
DOI: 10.1002/iid3.1032 PMID: 37773705
Cathelicidin LL-37 Activates Human Keratinocyte Autophagy through the P2X₇, Mechanistic Target of Rapamycin, and MAPK Pathways.
Risa Ikutama; Ge Peng; Saya Tsukamoto; Yoshie Umehara; Juan Valentin Trujillo-Paez; Hainan Yue; Hai Le Thanh Nguyen; Miho Takahashi; Shun Kageyama; Masaaki Komatsu; Ko Okumura; Hideoki Ogawa · The Journal of investigative dermatology · 2023
DOI: 10.1016/j.jid.2022.10.020 PMID: 36455652
Engineered Exosomes Containing Cathelicidin/LL-37 Exhibit Multiple Biological Functions.
Yajuan Su; Navatha Shree Sharma; Johnson V John; Gitali Ganguli-Indra; Arup K Indra; Adrian F Gombart; Jingwei Xie · Advanced healthcare materials · 2022
DOI: 10.1002/adhm.202200849 PMID: 35930707
Human Cathelicidin Peptide LL-37 Induces Cell Death in Autophagy-Dysfunctional Endothelial Cells.
Kaori Suzuki; Mari Ohkuma; Akimasa Someya; Tomoya Mita; Isao Nagaoka · Journal of immunology (Baltimore, Md. : 1950) · 2022
DOI: 10.4049/jimmunol.2100050 PMID: 35387840
Cathelicidin LL-37 Ignites Primed NLRP3 Inflammasomes in Rosacea.
David O Croitoru; Vincent Piguet · The Journal of investigative dermatology · 2021
DOI: 10.1016/j.jid.2021.04.024 PMID: 34565561
Efficacy of Cathelicidin LL-37 in an MRSA Wound Infection Mouse Model.
Oriana Simonetti; Oscar Cirioni; Gaia Goteri; Guendalina Lucarini; Elżbieta Kamysz; Wojciech Kamysz; Fiorenza Orlando; Giulio Rizzetto; Elisa Molinelli; Gianluca Morroni; Roberto Ghiselli; Mauro Provinciali · Antibiotics (Basel, Switzerland) · 2021
DOI: 10.1007/s10096-012-1663-1 PMID: 34680791
Cathelicidin LL-37 (an antimicrobial peptide)-induced colistin dependence in Acinetobacter baumannii.
Ji-Young Lee; Yoon-Kyoung Hong; Kwan Soo Ko · Diagnostic microbiology and infectious disease · 2020
DOI: 10.1016/j.diagmicrobio.2019.114965 PMID: 32019695
Salivary and serum cathelicidin LL-37 levels in subjects with rheumatoid arthritis and chronic periodontitis.
Chia Wei Cheah; Anis Rageh Al-Maleki; Jamuna Vadivelu; Mahmoud Danaee; Sargunan Sockalingam; Nor Adinar Baharuddin; Rathna Devi Vaithilingam · International journal of rheumatic diseases · 2020
DOI: 10.1111/1756-185X.13919 PMID: 32743970
The impact of cathelicidin, the human antimicrobial peptide LL-37 in urinary tract infections.
Ibrahim H Babikir; Elsir A Abugroun; Naser Eldin Bilal; Abdullah Ali Alghasham; Elmuataz Elmansi Abdalla; Ishag Adam · BMC infectious diseases · 2018
DOI: 10.1126/science.282.5393.1494 PMID: 29310594
Cathelicidin (LL-37) and human β2-defensin levels of children with post-infectious bronchiolitis obliterans.
Ahmet Hakan Gedik; Erkan Cakir; Yasemin Gokdemir; Zeynep Seda Uyan; Abdurrahim Kocyigit; Emel Torun; Bulent Karadag; Refika Ersu; Fazilet Karakoc · The clinical respiratory journal · 2017
DOI: 10.1111/crj.12331 PMID: 26073571
Cathelicidin (LL-37) level in the scalp hair of patients with tinea capitis.
Nagwa H Abdelaal; Laila A Rashed; Sahar Y Ibrahim; Mona H Abd El Halim; Noha Ghoneim; Noha A Saleh; Marwah A Saleh · Medical mycology · 2017
DOI: 10.1093/mmy/myw132 PMID: 27915299
Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases.
Karol Majewski; Paulina Żelechowska; Ewa Brzezińska-Błaszczyk · Clinical and investigative medicine. Medecine clinique et experimentale · 2017
DOI: 10.25011/cim.v40i1.28052 PMID: 28218580
Serum level of cathelicidin LL-37 in patients with active tuberculosis and other infectious diseases.
K Majewski; J Agier; E Kozłowska; E Brzezińska-Błaszczyk · Journal of biological regulators and homeostatic agents · 2017
PMID: 28956425
Serum levels of peptide cathelicidin LL-37 in elderly patients with depression.
Elżbieta Kozłowska; Adam Wysokiński; Ewa Brzezińska-Błaszczyk · Psychiatry research · 2017
DOI: 10.1016/j.psychres.2017.05.036 PMID: 28550757
Human cathelicidin LL-37 inhibits platelet aggregation and thrombosis via Src/PI3K/Akt signaling.
Wen Su; Yahui Chen; Caihui Wang; Xue Ding; Gamariel Rwibasira; Yi Kong · Biochemical and biophysical research communications · 2016
DOI: 10.1016/j.bbrc.2016.03.095 PMID: 27012197
Human cathelicidin, LL-37, inhibits respiratory syncytial virus infection in polarized airway epithelial cells.
Jennifer L Harcourt; Melissa McDonald; Pavel Svoboda; Jan Pohl; Kathleen Tatti; Lia M Haynes · BMC research notes · 2016
DOI: 10.1084/jem.188.10.1967 PMID: 26732674
Cathelicidin LL-37 peptide regulates endothelial cell stiffness and endothelial barrier permeability.
Fitzroy J Byfield; Qi Wen; Katarzyna Leszczynska; Alina Kulakowska; Zbigniew Namiot; Paul A Janmey; Robert Bucki · American journal of physiology. Cell physiology · 2011
DOI: 10.1152/ajpcell.00158.2010 PMID: 20943960
The human cathelicidin, LL-37, induces granzyme-mediated apoptosis in cytotoxic T lymphocytes.
Jamie S Mader; Marcelo Marcet-Palacios; Robert E W Hancock; R Chris Bleackley · Experimental cell research · 2011
DOI: 10.1016/j.yexcr.2010.11.015 PMID: 21134367
The human cathelicidin, LL-37, induces granzyme-mediated apoptosis in regulatory T cells.
Jamie S Mader; Catherine Ewen; Robert E W Hancock; Robert C Bleackley · Journal of immunotherapy (Hagerstown, Md. : 1997) · 2011
DOI: 10.1097/CJI.0b013e318207ecdf PMID: 21389875